Valuation: Ocugen, Inc.

Market Cap 498M 436M 402M 371M 704M 47.46B 716M 4.8B 1.88B 23.38B 1.87B 1.83B 80.45B P/E 2026 *
-6.51x
P/E 2027 * -6.07x
Enterprise Value 435M 381M 351M 325M 616M 41.5B 626M 4.2B 1.65B 20.44B 1.63B 1.6B 70.35B EV / Sales 2026 *
107x
EV / Sales 2027 * 45.2x
Free-Float
98.28%
Yield 2026 *
-
Yield 2027 * -
1 week-2.87%
Current month-5.03%
1 month+24.42%
3 months-14.74%
6 months+0.67%
Current year+0.71%
1 week 1.23
Extreme 1.23
1.34
1 month 1.01
Extreme 1.006
1.47
3 years 0.33
Extreme 0.3264
2.35
5 years 0.33
Extreme 0.3264
15.88
Manager TitleAgeSince
Chief Executive Officer 62 27/09/2019
Director of Finance/CFO - 09/02/2026
Chief Operating Officer - 01/03/2026
Director TitleAgeSince
Chairman 62 27/09/2019
Director/Board Member 59 01/09/2013
Director/Board Member 59 01/09/2019
Change 5-day change 1-year change 3-year change Capi.($)
+2.07%-2.87%+33.06%+137.87% 498M
+0.58%+2.06%+2.92%+10.86% 50.73B
-2.22%-1.25%+385.40%+586.81% 39.73B
-0.54%+0.39%+25.57%-5.28% 34.69B
-1.36%+0.35%+17.88%+55.14% 33.21B
+1.21%-4.58%+3.00%+35.46% 26.76B
-1.81%-1.48% - - 16.8B
+0.51%-3.47%+63.97%+122.60% 15.37B
+0.23%-0.58%+13.76%+21.11% 13.78B
-0.62%-3.09%+10.29%-31.35% 12.85B
Average -0.45%-0.83%+61.76%+103.69% 27.1B
Weighted average by Cap. -0.48%-0.23%+80.59%+124.35%

Financials

2026 *2027 *
Net sales 4.08M 3.57M 3.29M 3.04M 5.77M 389M 5.87M 39.35M 15.43M 192M 15.31M 14.98M 659M 11.02M 9.65M 8.9M 8.22M 15.6M 1.05B 15.85M 106M 41.71M 518M 41.37M 40.47M 1.78B
Net income -76.84M -67.33M -62.08M -57.36M -109M -7.33B -111M -742M -291M -3.61B -288M -282M -12.42B -85.3M -74.73M -68.9M -63.67M -121M -8.13B -123M -823M -323M -4.01B -320M -313M -13.79B
Net Debt -62.5M -54.76M -50.49M -46.65M -88.46M -5.96B -89.93M -603M -237M -2.94B -235M -230M -10.1B -
Logo Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Novel Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.
Employees
-
Date Price Change
10/07/26 €1.284 +2.07%
09/07/26 €1.258 -2.02%
08/07/26 €1.284 -1.38%
07/07/26 €1.302 +0.62%
06/07/26 €1.294 -2.12%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
1.470USD
Average target price
11.43USD
Spread / Average Target
+677.45%

Quarterly revenue - Rate of surprise